Trial Profile
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Study Evaluating the Efficacy and Safety of ALTU-135 Treatment in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Liprotamase (Primary)
- Indications Cystic fibrosis; Exocrine pancreatic insufficiency
- Focus Registrational; Therapeutic Use
- Acronyms DIGEST E
- Sponsors Alnara Pharmaceuticals
- 21 Jul 2014 New trial record